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Abstract 
Treatments for primary aldosteronism (PA) aim to correct or prevent the deleterious 
consequences of hyperaldosteronism: hypertension, hypokalemia and direct target organ 
damage. Patients with unilateral PA considered fit for surgery can undergo laparoscopic 
adrenalectomy, which significantly decreases blood pressure and medications in most cases, 
and cures hypertension in about 40%. Mineralocorticoid receptor antagonists (MRA) are used 
to treat patients with bilateral PA and those with unilateral PA if surgery is not possible or not 
desired. Spironolactone is more potent than eplerenone, but high doses are poorly tolerated in 
men. MRA can be replaced or complemented with epithelial sodium channel blockers, such as 
amiloride. Thiazide diuretics and calcium channel blockers are used when the first-line drugs 
are insufficient to control blood pressure. Dietary sodium restriction should be implemented 
in all cases, because the deleterious consequences of hyperaldosteronism are dependent on 
salt loading. Several studies comparing the results of surgery and MRA have reported no 
differences in terms of blood pressure, serum potassium concentration or cardiovascular and 
renal outcomes, although the benefits of treatment tend to be observed sooner with surgery. 
PA patients display relative glomerular hyperfiltration, which is reversed by specific 
treatment, revealing chronic kidney disease in 30% of patients. However, further kidney 
damage is prevented by the treatment of PA. 
 
Clinical summary 
- The goals of treatment are the normalization of serum potassium concentration, blood 
pressure control and prevention of the direct effects of excess aldosterone on target organs. 
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- The non-surgical treatment of PA is based on mineralocorticoid receptor antagonists and 
dietary sodium restriction. 
- Epithelial sodium channel blockers are used when mineralocorticoid receptor antagonists are 
not well tolerated; thiazide diuretics and calcium channel blockers are used when blood 
pressure control is insufficient with the first-line treatment. 
- Laparoscopic adrenalectomy is safe and decreases BP and medication requirements in 
patients with unilateral PA; drug-based treatments are appropriate in cases in which surgery is 
inappropriate or not desired. 
 
Keywords 
Hyperaldosteronism; Adrenalectomy; Mineralocorticoid receptor antagonists; Epithelial 
sodium channel blockers; Chronic kidney disease. 
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Introduction 
Primary aldosteronism (PA) is the state of autonomous aldosterone overproduction by one or 
both adrenal glands.
1
 Activation of the mineralocorticoid receptor increases the number of 
epithelial sodium channels (ENaC) and sodium chloride cotransporters (NCC) on the 
epithelial cell membrane of distal tubules and collecting ducts.
2
 This leads to sodium 
reabsorption and potassium secretion, resulting in an increase in plasma volume and 
hypokalemia. However, sodium availability in the distal tubule must exceed a certain amount 
for these consequences to occur. Hypertension results partly from an increase in plasma 
volume and partly from the aldosterone-mediated vasoconstriction of systemic arteries.
3
 
Target organ damage is mostly due to hypertension, but aldosterone also promotes oxidative 
stress, inflammation and fibrosis in the kidney and other organs (heart, vessels, adipose 
tissue). These effects are also dependent on salt loading and may be partly independent of the 
mineralocorticoid receptor.
4–6
 
 
Treatment aims to decrease the morbidity and mortality associated with PA and to improve 
the quality of life of patients. Economic constraints make it necessary to achieve these ends at 
the lowest possible cost. The most logical way to achieve these goals is to normalize 
aldosterone secretion. This is possible in patients with unilateral PA, through removal of the 
offending adrenal gland. Aldosterone synthase inhibitors are currently being developed but 
are not yet used in clinical practice.  
Mineralocorticoid receptor antagonists (MRAs) counteract most, but not all the biological 
effects of hyperaldosteronism. However, they yield clinical results comparable to those 
achieved by adrenalectomy. ENaC blockers impede only some of the many pathways leading 
to target organ damage, but are useful adjunctive treatments, together with dietary sodium 
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restriction, for controlling blood pressure (BP) and hypokalemia. Non-specific 
antihypertensive agents are often required in addition to these specific treatments, to control 
hypertension.  
 
We will begin by describing the principal treatments for PA — surgery and antihypertensive 
drugs — and reviewing their outcomes. We will then discuss the most appropriate uses of 
these treatments according to PA subtype, and the clinical circumstances and individual 
preferences of patients.  
 
Unilateral adrenalectomy 
The vast majority of adrenal lesions causing unilateral PA are small and benign, and are 
therefore ideal candidates for laparoscopic adrenalectomy, for which morbidity is lower and 
hospital stays are shorter than for open surgery.
7,8
 Several surgeons have advocated partial 
adrenalectomy as a safe and feasible way of removing single aldosterone-producing adenomas 
(APA).
9,10
 However, the benefits of this adrenal gland-sparing approach are questionable in 
PA, because contralateral tumors requiring subsequent adrenalectomy are very rare. 
Moreover, 10 to 25% of patients with unilateral PA have multiple adjacent nodules that may 
be missed on preoperative adrenal imaging, and the largest lesion is not necessarily the lesion 
responsible for PA.
11
 Several percutaneous alternatives for the destruction of APAs have been 
proposed, including ethanol injection, arterial embolization, cryoabalation and radiofrequency 
ablation.
11,12
 These techniques are less invasive than surgery, but the long-term outcome and 
risks are uncertain. They should therefore be used only within the confines of a study 
protocol. 
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Surgeons may opt for a transperitoneal or for a retroperitoneal approach. Both approaches 
have drawbacks and advantages. The lateral transperitoneal laparoscopic approach exposes 
the adrenal gland to a greater extent, whereas the retroperitoneal approach avoids facing 
adhesion in patients who have previously undergone intra-abdominal surgery, and potentially 
reduces the duration of the patient’s stay in hospital.13 Laparoscopic adrenalectomy usually 
requires three to four ports for the introduction of the instruments, but a single-port 
transumbilical approach is possible.
14,15
 Robot-assisted laparoscopic adrenalectomy is feasible 
and safe but more expensive, and its advantages over conventional laparoscopy have yet to be 
definitively demonstrated.
15–17
 
 
The mean operating time for laparoscopic adrenalectomy performed by experienced surgeons 
in major series is between one and two hours, and mean hospital stay is about three days.
18,19
 
Conversion to open surgery is required in less than 5% of cases.
8
 Perioperative mortality is 
less than 0.5%, non-fatal complications occur in 5% to 15% of cases and most of them are 
benign (temporary relaxation and/or hypoesthesia of the abdominal wall).
7,8,18
 Fewer than 2% 
of patients experience severe complications: hemorrhage requiring transfusion, cardiac or 
respiratory destabilization.
7,8,18
 However, cases of major complications have been reported 
outside of referral centers.
20
 Surgery should be performed by an experienced surgeon at an 
institution with a high volume of such interventions. In such settings, outpatient laparoscopic 
adrenalectomy is possible in selected cases: patients under the age of 65 years, tumors of less 
than 6 cm in diameter, no significant cardiorespiratory disease, first case of the day to be 
managed in the surgical program, residence less than 30 minutes from the hospital by car, and 
treatment with no more than three antihypertensive agents.
21–23
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Patients should be treated with a MRA and potassium supplements to lower BP and to correct 
hypokalemia before surgery. Preoperative mineralocorticoid receptor blockade for a few 
weeks before surgery may also decrease the risk of postoperative hypoaldosteronism due to 
the chronic suppression of aldosterone secretion in the contralateral gland. Nonetheless, 
postoperative hyperkalemia is seen in up to 30% of patients.
24,25
 It is usually mild and 
transient, but MRA treatment and potassium supplements should be discontinued at the time 
of surgery, to minimize the risk, and serum potassium concentrations should be monitored 
closely, particularly in patients with chronic kidney disease (CKD).
25
 In addition to the 
restriction of potassium-rich food, fludrocortisone has been used in rare cases of persistent 
hyperkalemia due to postoperative hypoaldosteronism.
24
 Hormonal studies should be carried 
out for patients with high BP after surgery, to distinguish between persistent PA and  
associated essential hypertension. 
 
Outcomes of adrenalectomy in unilateral PA 
We discuss here the findings of a systematic review of large surgical series published since 
2000.
11
 This time limit was set to correspond to current outcomes of laparoscopic surgery in 
patients with unilateral PA diagnosed with current protocols. This evidence base is 
nonetheless limited by the lack of comparison with drug-based treatment and medium-term 
evaluations of mostly intermediate outcomes (BP, serum potassium, subclinical target organ 
damage). 
 
By definition, unilateral adrenalectomy should normalize aldosterone secretion in all cases of 
unilateral PA. However, 5 to 10% of patients display residual autonomous aldosterone 
production after surgery, even if hypertension is cured
26
 and adrenal venous sampling (AVS) 
is used in the diagnostic process. Hypokalemia, when present, resolves in more than 95% of 
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cases, in all series. The mean rate of hypertension cure is 40%, with a high variability between 
series. Patients with persistent hypertension nonetheless experience a clinically significant 
decline in BP (of between 20 and 40 mmHg for systolic BP) and a decrease in the number of 
antihypertensive drug classes used (one or two fewer). Less than 25% of patients experience 
no apparent BP benefit from surgery.  
 
An increase in markers of oxidative stress is observed more frequently in patients with PA 
than in patients with essential hypertension, and the levels of these markers decrease 
significantly after adrenalectomy in patients with unilateral disease.
27
 
 
Patients with PA have higher cardiovascular morbidity and greater subclinical organ damage 
than expected on the basis of their BP.
28
 Many studies have shown that left ventricular mass 
decreases and that aortic pulse wave velocity and carotid intima-media thickness improve 
after adrenalectomy.
29–35
 A prospective study compared cardiovascular events in 54 PA 
patients treated by adrenalectomy (unilateral disease) or with spironolactone (unilateral or 
bilateral disease) with 323 patients with essential hypertension.
36
 The composite endpoint was 
myocardial infarction, stroke, any type of revascularization procedure, and sustained 
arrhythmia. Its incidence over a mean follow-up of 7.4 years did not differ between patients 
with treated PA and their controls (who achieved similar BP levels throughout follow-up). A 
study with a similar design found the incidence of cardiovascular events — acute coronary 
events, stroke, sustained arrhythmia, hospitalization for heart failure — to be slightly higher 
in 270 PA patients after specific treatment than in 810 matched patients with essential 
hypertension over a median follow-up period of 12 years.
37
 These discrepancies may be due 
to the higher rate of incident hospitalization for heart failure in PA patients than in controls in 
the second study, this outcome not being considered in the first study. 
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A worsening of kidney function after adrenalectomy was first reported one year after Jerome 
Conn described the first APA.
38
 By contrast to otherwise similar patients with essential 
hypertension, patients with PA display relative glomerular hyperfiltration, defined as a high 
estimated glomerular filtration rate (eGFR) and low-grade albuminuria.
39
 These changes are 
associated with lower intrarenal arterial resistance and higher rates of blood flow in the 
kidney.
40
 They are most marked in patients with unilateral PA
41,42
 and are reversed within one 
month of adrenalectomy (Figure 1).
40,43–55
 Hemodynamic stress and hyperaldosteronism per 
se lead to chronic structural damage in the long run.
45,56
 
 
PA patients have been reported to display a certain level of insulin resistance, which may 
improve after adrenalectomy.
57,58
 However, PA patients have the same likelihood of clinically 
defined glucose and lipid metabolism disorders at diagnosis as similar patients with essential 
hypertension, and adrenalectomy does not improve their clinical metabolic profile.
37,59,60
 
 
One study suggests that the subjective well being of patients with unilateral PA, which is 
lower at baseline than that of the general population, significantly improves after 
adrenalectomy.
61
  
 
Drug-based treatment for PA 
As the deleterious consequences of hyperaldosteronism depend on salt loading, dietary salt 
reduction is a cornerstone of medical treatment. A strict low-salt diet as the sole intervention 
in patients with PA reduces BP, restores the nocturnal dip in BP and lessens hypokalemia.
62–64
 
Moreover, dietary salt reduction greatly potentiates the effect of spironolactone.
65
 However, 
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strict compliance with a low-salt diet is as difficult to achieve in PA patients as in other 
subjects. 
 
Spironolactone is a potent, cheap but non-selective MRA. The usual daily dose of 
spironolactone required to achieve normokalemia and a significant decrease in BP in patients 
with PA ranges from 50 mg to 200 mg, and the published evidence was obtained from studies 
involving daily doses of 100 mg or more.
66
 However, adverse effects of this drug, due to its 
anti-androgenic and anti-progesterone activity, limit the use of such doses in many men and 
some women. Doses below 50 mg/day are usually well tolerated,
67
 but are not always 
sufficient to correct PA completely. Eplerenone, a selective MRA, is an appealing alternative 
in settings where its use for PA is approved.
68
 However, double the dose is required to 
achieve an efficacy similar to that of spironolactone for lowering BP, and the ceiling effect 
appears to occur sooner: a 10 mmHg decreased in systolic BP at most, versus 25 mmHg for 
spironolactone.
69
 Moreover, eplerenone must be administered twice daily to ensure activity 
throughout the day and is currently more expensive than spironolactone.  
 
Amiloride is an ENaC blocker that opposes the reabsorption of sodium in exchange for 
potassium in the distal tubules and collecting ducts. In most countries, it is available in the 
form of 5 mg tablets, although the usual daily dose required to correct hyperaldosteronism 
effectively is 10 to 40 mg.
70
 Its half life is 8 hours, and twice-daily intake is therefore required 
for an optimal effect. Triamterene is another ENaC blocker.
71,72
 In many countries, 
triamterene is only available in combination with thiazide diuretics. Amiloride (or 
triamterene) can be used to complement the highest well tolerated dose of spironolactone: as a 
rule of thumb, 10 mg amiloride or 100 mg triamterene prevent potassium wastage as 
effectively as 25 mg spironolactone.
70,72
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The long-term use of potassium supplements is undesirable. They are costly and cause 
gastrointestinal discomfort. Slow-release tablets are better tolerated but may cause esophageal 
and gastrointestinal ulcerations. Appropriate doses of spironolactone or amiloride are always 
sufficient to correct hypokalemia. Serum potassium concentration should be monitored 7 to 
15 days after each change in the dose of potassium-sparing diuretics (MRAs, ENaC blockers). 
 
MRAs, even if used in combination with ENaC blockers, are often insufficient to control BP. 
The most logical adjunctive treatments are thiazide diuretics and calcium channel blockers 
(CCB). Thiazide diuretics potentiate natriuresis, helping to decrease plasma volume. They act 
in synergy with spironolactone and ENaC blockers.
65,71
 In patients with low eGFR, they can 
be replaced by loop diuretics. Several dihydropyrine calcium channel antagonists weakly 
antagonize the mineralocorticoid receptor or inhibit key enzymes of aldosterone biosynthesis 
(most notably CYP1B2).
73,74
 Nifedipine, nitrendipine and felodipine are the available 
molecules with the greatest antialdosterone potency. Nifedipine has been tested as a 
monotherapy in 10 PA patients, and was shown to have a significant effect on BP, serum 
potassium and aldosterone concentrations at four weeks.
75
 Beta-blockers, angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aliskiren are 
probably not the best choices for decreasing BP in PA patients, because renin activity is 
chronically suppressed in these patients.
76
 However, ARBs may be beneficial in some patients 
with bilateral hyperplasia or angiotensin-responsive adenoma.
77,78
 
 
Finerenone, a new non-steroidal and highly potent MRA, has been studied in patients with 
chronic heart failure and mild CKD; it seems to decrease BNP and albuminuria as efficiently 
as spironolactone.
79,80
 Aldosterone synthase inhibitors are currently in clinical development. 
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For instance, LCI699 has been tested in patients with PA, with mixed results: aldosterone 
secretion was decreased, but this did not translate into a lowering of BP. Moreover, the drug 
induced a blunted glucocorticoid response to ACTH of uncertain clinical significance.
81,82
  
 
Outcomes of drug-based treatment 
No randomized study has compared the BP outcome of adrenalectomy with that of specific 
drugs in patients with unilateral PA. However, drug-based treatment in 24 patients with 
unilateral PA led to normokalemia in all patients and long-lasting BP decreases of  a 
magnitude similar to that observed in surgical series.
83
 Moreover, a prospective study showed 
that the BP-lowering effect of high-dose spironolactone was similar to, or even slightly 
greater than that of subsequent adrenalectomy in 44 patients.
84
 
 
Spironolactone may appear to be less potent than adrenalectomy for improving left ventricular 
hypertrophy, but studies with long-term follow-up have shown that the same improvement is 
ultimately achieved, even though the regression of left ventricular mass is slower with 
spironolactone than with adrenalectomy.
29,34,85
 The benefits of PA treatment were similar for 
specific drugs and surgery in both studies comparing the incidence of cardiovascular events in 
treated PA patients and matched controls with essential hypertension.
36,37
 
 
The relative glomerular hyperfiltration and microalbuminuria of PA patients are corrected on 
specific drugs (Figure 1).
40,44–46,50,51,53–55
 Spironolactone was found to be less effective than 
surgery for achieving this end in one study using a fixed low dose (50 mg/day).
50
 Five other 
studies, with spironolactone uptitrated as needed and tolerated, revealed effects no different 
from those of surgery.
44–46,48,53,55
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PA patients treated with spironolactone or amiloride experience an improvement in well-
being similar to that observed after adrenalectomy, although these effects appear to be 
established more slowly.
86
 
 
Treatment choice as a function of PA subtype 
Adrenal carcinomas are very rare (1-2/million subjects/year) and present as isolated PA in less 
than 5% of cases. Carcinomas are often irregular and exceed 40 mm in size; their spontaneous 
density on adrenal CT is > 10 UH, with heterogeneous enhancement and slow contrast 
washout, and they may infiltrate surrounding tissues and invade adjacent organs.
87
 Resection 
by open surgery is the cornerstone of treatment, except for carcinomas with distant 
metastases. 
 
Familial hyperaldosteronism type 1 or glucocorticoid-remediable aldosteronism (GRA) is also 
very rare. Patients with this disorder have a chimeric gene, placing aldosterone synthase 
transcription under the control of ACTH, causing bilateral PA. Autosomal dominant 
inheritance results in familial clusters of cases. Low-dose dexamethasone (0.125 to 0.25 
mg/day) or low-dose prednisone (2.5 to 5 mg/day) at bedtime efficiently suppresses ACTH 
secretion, thereby decreasing the ACTH-dependent hyperaldosteronism.
88
 The following 
characteristics of patients should lead to genetic testing: early primary aldosteronism (< 30 
years old) or early cerebrovascular events (< 50 years old), in the patient or a close relative.
89
 
 
For the more common causes of PA, treatment options depend on lateralization: unilateral PA 
is amenable to adrenalectomy, whereas bilateral PA generally is not. Adrenal venous 
sampling (AVS) is recommended to compare the aldosterone secretion of the two adrenal 
glands.
88,90,91
 AVS is invasive, performed only at referral centers and its use is based on a 
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pathophysiological rationale rather than solid clinical evidence.
42,92
 However, the rate of 
complications is low and no better supported alternative has yet been identified.
93
 Guidelines 
have recently been published, with the aim of decreasing the heterogeneity of AVS protocols 
and interpretation criteria, although the evidence supporting the recommendations is weak.
94
  
 
Subtype diagnosis, and hence AVS, is required only if surgery is being considered. Some 
factors are significantly associated with persistent hypertension after surgery:
11
 being male, 
advanced age, familial hypertension, longer duration and higher grade of hypertension, higher 
body mass index, higher serum potassium concentration, lower glomerular filtration rate, 
higher 24h urinary aldosterone secretion, subclinical target organ damage. However, none of 
these predictors has been consistently confirmed in all published series. Moreover, their 
predictive value at the individual level is limited. Typically, a patient with an unfavorable 
profile still has a 25% chance of being cured of hypertension by adrenalectomy
95
 and, even if 
hypertension persists, the patient will experience a significant decrease in BP and/or treatment 
requirements.
92
 Moreover, the normalization of aldosterone secretion probably has BP-
independent benefits. Factors predictive of the persistence of hypertension after 
adrenalectomy should not, therefore, be used as arguments for or against surgery in individual 
cases.  
 
Surgery should be considered an option in all patients without contraindication who are 
willing to undergo AVS, followed by adrenalectomy if lateralization is demonstrated. Unlike 
the drugs currently available, surgery normalizes aldosterone secretion, thereby preventing all 
the effects of aldosterone overproduction. However, as we have seen above, this theoretical 
advantage does not translate into a proven clinical advantage over specific drug treatment.  
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The most consistent argument for surgery in unilateral PA is that it eliminates or decreases the 
need for drug treatment and the economic and psychological burden that such drug treatment 
entails. A primitive cost-effectiveness analysis found that adrenalectomy, with a 35% cure 
rate and a 85% improvement rate, was a cost-saving option for 50-year-old PA patients, as it 
eliminated the need for lifelong drug therapy.
96
 Another more thorough cost-effectiveness 
analysis suggested that, for PA patients with a life expectancy of more than 25 years, 
performing AVS in all patients and adrenalectomy in those displaying lateralization would be 
cheaper than not carrying out AVS and providing lifelong drug treatment for all patients.
97
 
However, the assumptions of the model (cure rate; cost of medical treatment, AVS and 
surgery) may not extend to all settings. 
 
Younger patients have a longer life expectancy and therefore derive greater benefit from 
surgery. The risk of anesthesia is also smallest in this group of patients. The early diagnosis of 
unilateral PA is therefore important. Patients with resistant hypertension may also derive a 
significant benefit from surgery, particularly if compliance is an issue or if spironolactone is 
ineffective or not well tolerated. The benefit-risk ratio is less positive in older patients, 
particularly if there are compelling indications for antihypertensive drugs, which must be 
continued irrespective of BP levels. This is the case for beta-blockers for coronary artery 
disease and for ACE inhibitors and spironolactone for heart failure. 
 
Only the few patients at high surgical risk and those with a short life expectancy should be 
advised against surgery. However, patients should not be coerced into considering surgery if 
they prefer not to undergo the procedure, given that there is reasonable evidence to suggest 
that lifelong treatment with mineralocorticoid antagonists is a valid alternative to surgery. 
Treatment choice should therefore also be driven by the preferences of the patient. Candidates 
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for surgery should be told that the presence of an APA poses no risk in terms of cancer. They 
should also be informed that the clinical outcomes of surgery and medication are similar, that 
hypertension is cured by surgery in only 40% of cases but that medication levels and BP are 
lowered even in those not cured, and that, in the absence of surgery, medication is lifelong 
and not always well tolerated. Patients may opt for a trial period on spironolactone before 
deciding whether to consider surgery and, therefore, to undergo AVS. 
 
Patients with bilateral PA and those who refuse or have a contraindication for surgery should 
be treated with spironolactone, beginning with a dose of 25 mg/day, with uptitration until 
kalemia and blood pressure are normalized. Dietary sodium restriction should be actively 
promoted, because the deleterious consequences of hyperaldosteronism depend on salt 
loading. If spironolactone is poorly tolerated, the highest accepted dose should be 
complemented with amiloride, starting at a dose of 5 mg twice daily, with uptitration as 
required. Eplerenone can be used instead of this spironolactone-amiloride combination in 
settings in which it is approved for the treatment of hypertension, provided that the patient can 
afford it. We favor the spironolactone-amiloride combination over eplerenone because a 
beneficial impact on clinical events has been shown with spironolactone but not yet with 
eplerenone. If BP remains uncontrolled despite potassium-sparing diuretics, thiazide or loop 
diuretics and CCB should be added, as required. Unilateral adrenalectomy has been 
performed in a few patients with presumed bilateral disease refractory to drug treatment or 
unable to tolerate optimal medical management.
98
 Hypertension was cured or improved in 
about one third of these patients, particularly those with mild PA or one dominant adrenal 
gland on AVS, even though the lateralization criterion was not met. 
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CKD affects the clinical profile of patients with PA and the effectiveness and risk associated 
with treatment options; it must therefore be taken into account when clinical decisions are 
made (Table 1). 
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Table 1. Particularities of primary aldosteronism (PA) treatment in patients with chronic 
kidney disease (CKD) 
Surgical treatment 
 Contrast nephropathy is a specific concern when planning to perform adrenal venous 
sampling in CKD patients to identify those who could undergo adrenalectomy. 
However, complications are rare with appropriate hydration and the smallest possible 
amount of a low-osmolar contrast medium (less than 50 ml).
99
 
 Patients with CKD are at risk of hyperkalemia after adrenalectomy. Mineralocorticoid 
receptor antagonist treatment and potassium supplements should be discontinued 
immediately after surgery and serum potassium concentrations should be monitored 
closely.
25
  
 Adrenalectomy also unmasks postoperative eGFR below 60 ml/min/1.73m² in 30% to 
40% of patients with unilateral PA.
52,54,55
 It is more likely in patients who have a 
preoperative eGFR that is already close to this threshold.
54
 
Drug-based treatment 
 The pharmacokinetics of spironolactone and eplerenone are unaffected in patients with 
CKD.
100
 Amiloride is partly excreted in the urine and its half-life is longer in patients 
with CKD, so lower doses and once-daily intakes can be used. Triamterene 
crystallizes in the urine, causing nephrolithiasis and acute kidney injury. It should not 
be used in patients with CKD. 
 Patients with CKD are prone to hyperkalemia with potassium-sparing diuretics 
(mineralocorticoid receptor and epithelial sodium channel blockers). However, 
patients with CKD are likely to require higher doses of mineralocorticoid blockers, 
due to their antiproteinuric and antifibrosing effects.
101
 The initiation of treatment at a 
low dose and slow upward titration are advised.
100
 Serum potassium concentration 
should be monitored within 7 days of each change in the dose of potassium-sparing 
diuretics.  
 Several drugs potentiate potassium retention and should be used with caution: beta-
blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, 
aliskiren, nonsteroidal anti-inflammatory drugs, heparins, trimethoprim, and 
calcineurin inhibitors. Loop diuretics and low-potassium diet can help to control 
hyperkalemia in patients with advanced CKD who are taking potassium-sparing 
diuretics. 
 Finerenone, a new non-steroidal mineralocorticoid receptor antagonist seems to be as 
effective as spironolactone and results in lower levels of hyperkalemia in patients with 
mild CKD.
79
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Figure 1. Kidney function decline after the specific treatment of primary aldosteronism 
 
*standardized mean differences are expressed as the number of observed standard deviations 
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